403 related articles for article (PubMed ID: 26324360)
21. Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells.
Simpkins F; Jang K; Yoon H; Hew KE; Kim M; Azzam DJ; Sun J; Zhao D; Ince TA; Liu W; Guo W; Wei Z; Zhang G; Mills GB; Slingerland JM
Clin Cancer Res; 2018 Oct; 24(19):4874-4886. PubMed ID: 29959144
[No Abstract] [Full Text] [Related]
22. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
[TBL] [Abstract][Full Text] [Related]
23. Low-grade epithelial ovarian cancer: a number of distinct clinical entities?
Oswald AJ; Gourley C
Curr Opin Oncol; 2015 Sep; 27(5):412-9. PubMed ID: 26241347
[TBL] [Abstract][Full Text] [Related]
24. MEK1 mutations confer resistance to MEK and B-RAF inhibition.
Emery CM; Vijayendran KG; Zipser MC; Sawyer AM; Niu L; Kim JJ; Hatton C; Chopra R; Oberholzer PA; Karpova MB; MacConaill LE; Zhang J; Gray NS; Sellers WR; Dummer R; Garraway LA
Proc Natl Acad Sci U S A; 2009 Dec; 106(48):20411-6. PubMed ID: 19915144
[TBL] [Abstract][Full Text] [Related]
25. Targeting the mitogen-activated protein kinase pathway in low-grade serous carcinoma of the ovary.
McLachlan J; Gore M; Banerjee S
Pharmacogenomics; 2016 Aug; 17(12):1353-63. PubMed ID: 27469379
[TBL] [Abstract][Full Text] [Related]
26. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
Ricciardelli C; Lokman NA; Pyragius CE; Ween MP; Macpherson AM; Ruszkiewicz A; Hoffmann P; Oehler MK
Oncotarget; 2017 Mar; 8(11):17819-17832. PubMed ID: 28147318
[TBL] [Abstract][Full Text] [Related]
27. [Clinical significance and distribution of BRCA genes mutation in sporadic high grade serous ovarian cancer].
Liu WL; Wang ZZ; Zhao JZ; Hou YY; Wu XX; Li W; Dong B; Tong TT; Guo YJ
Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):26-31. PubMed ID: 28190312
[No Abstract] [Full Text] [Related]
28. TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
Brachova P; Mueting SR; Carlson MJ; Goodheart MJ; Button AM; Mott SL; Dai D; Thiel KW; Devor EJ; Leslie KK
Int J Oncol; 2015 Feb; 46(2):607-18. PubMed ID: 25385265
[TBL] [Abstract][Full Text] [Related]
29. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
[TBL] [Abstract][Full Text] [Related]
30. Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC).
Spreafico A; Oza AM; Clarke BA; Mackay HJ; Shaw P; Butler M; Dhani NC; Lheureux S; Wilson MK; Welch S; Zhang T; Yu C; Stockley T; Siu LL; Kamel-Reid S; Bedard PL
Gynecol Oncol; 2017 Feb; 144(2):250-255. PubMed ID: 28062115
[TBL] [Abstract][Full Text] [Related]
31. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer.
Ouellet V; Guyot MC; Le Page C; Filali-Mouhim A; Lussier C; Tonin PN; Provencher DM; Mes-Masson AM
Int J Cancer; 2006 Aug; 119(3):599-607. PubMed ID: 16572426
[TBL] [Abstract][Full Text] [Related]
32. Involvement of DPP9 in gene fusions in serous ovarian carcinoma.
Smebye ML; Agostini A; Johannessen B; Thorsen J; Davidson B; Tropé CG; Heim S; Skotheim RI; Micci F
BMC Cancer; 2017 Sep; 17(1):642. PubMed ID: 28893231
[TBL] [Abstract][Full Text] [Related]
33. Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR.
Bösmüller H; Fischer A; Pham DL; Fehm T; Capper D; von Deimling A; Bonzheim I; Staebler A; Fend F
Hum Pathol; 2013 Mar; 44(3):329-35. PubMed ID: 23089489
[TBL] [Abstract][Full Text] [Related]
34. Low-grade serous carcinoma: molecular features and contemporary treatment strategies.
Angarita AM; Cholakian D; Fader AN
Expert Rev Anticancer Ther; 2015; 15(8):893-9. PubMed ID: 26040191
[TBL] [Abstract][Full Text] [Related]
35. KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine.
Stewart ML; Tamayo P; Wilson AJ; Wang S; Chang YM; Kim JW; Khabele D; Shamji AF; Schreiber SL
Cancer Res; 2015 Jul; 75(14):2897-906. PubMed ID: 25968887
[TBL] [Abstract][Full Text] [Related]
36. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
37. Tumor evolution and intratumor heterogeneity of an epithelial ovarian cancer investigated using next-generation sequencing.
Lee JY; Yoon JK; Kim B; Kim S; Kim MA; Lim H; Bang D; Song YS
BMC Cancer; 2015 Feb; 15():85. PubMed ID: 25881093
[TBL] [Abstract][Full Text] [Related]
38. The highs and lows of serous ovarian cancer.
Grisham RN; Manning-Geist BL; Chui MH
Cancer; 2023 Sep; 129(17):2613-2620. PubMed ID: 37366225
[TBL] [Abstract][Full Text] [Related]
39. MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer.
Pénzváltó Z; Lánczky A; Lénárt J; Meggyesházi N; Krenács T; Szoboszlai N; Denkert C; Pete I; Győrffy B
BMC Cancer; 2014 Nov; 14():837. PubMed ID: 25408231
[TBL] [Abstract][Full Text] [Related]
40. Nuclear G protein-coupled oestrogen receptor (GPR30) predicts poor survival in patients with ovarian cancer.
Zhu CX; Xiong W; Wang ML; Yang J; Shi HJ; Chen HQ; Niu G
J Int Med Res; 2018 Feb; 46(2):723-731. PubMed ID: 29239277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
